Quality and Safety Imperatives in the Identification and Management of Hereditary Cancer Syndromes
Seminars in Oncology Nursing · 2026-04 · 42 (2) · 152174
DOI: 10.1016/j.soncn.2026.152174 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Oncology Nursing, 2026-04. Verfasst von Kathleen Calzone und 2 weiteren Autor:innen. Beteiligte Einrichtung: Genomic Healthcare Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Elec…. Hauptthemen laut MEDLINE: Neoplastic Syndromes, Hereditary, Genetic Testing, Quality of Health Care, Patient Safety. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Institutes of Health, National Cancer Institute.
Abstract (Originalsprache)
Objectives
We sought to provide an evidence review of the rapidly expanding technologies and sciences that have moved the field of hereditary cancers from niche to mainstream in current cancer care. This shift mandates that all oncology clinicians have foundational knowledge regarding the identification, testing, and management of patients and families at risk for hereditary cancer. Many cancers have established germline biomarker testing recommendations (breast, ovarian, pancreatic, metastatic prostate, colon), and in many of these cancer types, somatic biomarker tests are also considered standard of care. Unfamiliarity with the complexity of care in hereditary cancer leads to missed opportunities for cancer prevention and guideline-concordant genomic-informed care. Indeed, appropriately ordered, interpreted, and applied germline biomarker testing is a critical quality care indicator. Moreover, preventing harm from overlooked or inappropriate germline biomarker testing and incorrect result interpretation leads to optimal cancer prevention and effective cancer treatment. This is a central safety aspect in this rapidly changing landscape.
Methods
A review of peer-reviewed literature.
Results
Based on the literature review, the Five Rights of Germline Biomarker Testing for Hereditary Cancer is offered as a quality and safety framework. Accurate construction and interpretation of the pedigree continue to be a critical risk assessment tool. A comprehensive view of patient factors, family history, tumor pathology, and somatic biomarker test results is essential for quality care in hereditary cancers.
Conclusion
Oncology clinicians must be familiar with and refer to the most recent and updated versions of guidelines from reputable authorities, as the testing criteria shift frequently.
Implications for Nursing
Practice: The five rights framework offers clinicians a guide to safe practice in this ever-changing landscape.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Genomic Healthcare Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. Electronic address: calzonek@mail.nih.gov.
- Division of Hematology/Oncology, Department of Internal Medicine, Saint Louis University, St. Louis, MO.
- Loyola University Chicago, Marcella Niehoff School of Nursing.
Förderung
- Intramural NIH HHS
- National Institutes of Health
- National Cancer Institute
- Center for Cancer Research
Zitieren
APA
Calzone, K., Mahon, S. M., & Friend, P. (2026). Quality and Safety Imperatives in the Identification and Management of Hereditary Cancer Syndromes. Seminars in Oncology Nursing, 42(2), 152174. https://doi.org/10.1016/j.soncn.2026.152174
Vancouver
Calzone K, Mahon SM, Friend P. Quality and Safety Imperatives in the Identification and Management of Hereditary Cancer Syndromes. Seminars in Oncology Nursing. 2026;42(2):152174. doi:10.1016/j.soncn.2026.152174
BibTeX
@article{Calzone2026,
author = {Calzone, Kathleen and Mahon, Suzanne M and Friend, Patricia},
title = {Quality and Safety Imperatives in the Identification and Management of Hereditary Cancer Syndromes},
journal = {Seminars in Oncology Nursing},
year = {2026},
volume = {42},
number = {2},
pages = {152174},
doi = {10.1016/j.soncn.2026.152174}
}
EUVIMED